Daily Cardiology Research Analysis
Three studies with immediate clinical relevance stood out: a prospective registry shows that deferring left main revascularization using iFR yields outcomes comparable to intervention; a nationwide cohort links higher infective endocarditis risk to TAVI versus surgical valves; and a systematic review suggests pulmonary artery catheter–guided management may improve survival in cardiogenic shock, especially when shock is heart failure–related.
Summary
Three studies with immediate clinical relevance stood out: a prospective registry shows that deferring left main revascularization using iFR yields outcomes comparable to intervention; a nationwide cohort links higher infective endocarditis risk to TAVI versus surgical valves; and a systematic review suggests pulmonary artery catheter–guided management may improve survival in cardiogenic shock, especially when shock is heart failure–related.
Research Themes
- Physiology-guided coronary decision-making (iFR for left main)
- Valve selection and infective endocarditis risk (TAVI vs SAVR)
- Hemodynamic monitoring in cardiogenic shock (pulmonary artery catheter)
Selected Articles
1. Deferred revascularization of left main stenosis based on instantaneous wave-free ratio: Long-term clinical outcomes from the PHYNAL registry.
In a prospective multicenter registry of 240 patients with intermediate left main disease, deferring revascularization using an iFR cutoff of 0.89 produced similar 2‑year outcomes to proceeding with revascularization. MACE was 10% with deferral vs 16% with intervention (HR 1.56; p=0.30), with no significant differences in death, MI, or TLR.
Impact: This study supports physiology-guided deferral of left main revascularization, a high-stakes decision traditionally favoring intervention, potentially reducing unnecessary procedures.
Clinical Implications: For intermediate LM lesions, using iFR (cutoff 0.89) can safely defer revascularization with comparable 2-year outcomes, supporting routine physiology-guided decision-making and shared decision discussions.
Key Findings
- Among 240 patients, 188 were deferred and 52 revascularized based on iFR 0.89.
- MACE at median 24 months: 10% (deferral) vs 16% (revascularization), HR 1.56 (95% CI 0.67–3.60), p=0.30.
- No significant differences in all-cause death (5% vs 12%), cardiac death (3% vs 8%), non-fatal MI (1% vs 2%), or TLR (5% vs 2%).
Methodological Strengths
- Prospective multicenter registry with pre-specified iFR cutoff (0.89).
- Clinically meaningful composite and component endpoints with 2-year follow-up.
Limitations
- Nonrandomized design with potential residual confounding.
- Modest sample size for left main disease and limited power for rare events.
Future Directions: Randomized trials comparing iFR-guided deferral vs revascularization for LM lesions and studies assessing cost-effectiveness and patient-reported outcomes.
BACKGROUND: An accurate assessment of intermediate left main (LM) stenoses is crucial for revascularization decision-making. However, data on LM revascularization strategy according to instantaneous wave-free ratio (iFR) are limited. This study aimed to evaluate the safety of deferring LM revascularization according to iFR. METHODS: The PHYNAL study is a prospective, multicenter registry that included consecutive patients with intermediate LM stenosis who underwent coronary physiology assessment. Patients in whom the treatment strategy (revascularization versus deferral) was based on the iFR cutoff of 0.89 were considered for the current subanalysis. The primary endpoint was major adverse cardiac events (MACE), a composite outcome including all-cause death, non-fatal myocardial infarction (MI), and target lesion revascularization (TLR). Secondary endpoints were cardiac death and each component of the primary endpoint. RESULTS: The study population consisted of 240 patients: 188 in the deferred and 52 in the revascularized groups. At a median follow-up of 24 months (IQR: 21 to 25 months), MACE occurred in 19 patients (10 %) in the deferred and 8 patients (16 %) in the revascularized groups (HR: 1.56; 95 % CI: 0.67 to 3.60; p = 0.30) with no significant difference. Rate of all-cause death was 5 % in the deferred versus 12 % in the revascularized groups (p = 0.1), cardiac death 3 % versus 8 % (p = 0.2), non-fatal MI 1 % versus 2 % (p = 0.4), and TLR 5 % versus 2 % (p = 0.5). CONCLUSIONS: Deferring LM revascularization according to iFR is safe. Patients in whom LM revascularization is deferred based on iFR have comparable clinical outcomes to patients who undergo LM revascularization according to iFR.
2. Infective endocarditis and cardiac events after transcatheter vs surgical aortic valve replacement: A nationwide cohort study.
In a Swiss nationwide, propensity-matched cohort of 18,253 aortic valve replacements, infective endocarditis incidence was highest early post-procedure and was significantly higher after TAVI than bioprosthetic SAVR, and higher after bioprosthetic than mechanical SAVR. MACE rates followed a similar pattern.
Impact: Defines comparative IE risk across valve modalities at scale, informing valve selection, patient counseling, and surveillance strategies.
Clinical Implications: Heightened IE vigilance is warranted in the first 3 months post-replacement. When feasible, mechanical SAVR may confer lowest IE risk; TAVI recipients may benefit from intensified early surveillance and stringent infection prevention.
Key Findings
- 18,253 procedures analyzed; IE incidence highest within 3 months post-procedure.
- After matching, IE risk higher with TAVI vs bioprosthetic SAVR (HR 1.56; 95% CI 1.12–2.18).
- Bioprosthetic SAVR had higher IE risk than mechanical SAVR (HR 2.27; 95% CI 1.24–4.15).
- MACE hazards were elevated in TAVI vs bioSAVR and in bioSAVR vs mechSAVR.
Methodological Strengths
- Nationwide population-based dataset with propensity-score matching.
- Time-to-event analyses and reporting of incidence rate differences and hazards.
Limitations
- Observational design with potential residual confounding and coding inaccuracies.
- Limited procedural/microbiological granularity (e.g., prophylaxis details, pathogens).
Future Directions: Studies to identify modifiable IE risk factors post-TAVI, evaluate prophylaxis/antibiotic strategies, and refine early surveillance protocols.
OBJECTIVES: To compare rates of infective endocarditis (IE) and major adverse cardiac events (MACE) in patients with TAVI, bioprosthetic (bio), and mechanical (mech) SAVR. METHODS: Population-based cohort study of inpatient adults undergoing TAVI, bioSAVR or mechSAVR for aortic valve stenosis between 2012 and 2021 in Switzerland. In 2 pairwise 1:1 propensity-score matched cohorts (TAVI versus bioSAVR and bioSAVR versus mechSAVR) we analysed the primary outcome of the incidence of IE and secondary outcomes including MACE. RESULTS: Among 18,253 patients undergoing aortic valve replacement (mean age 76.6±10.3 years, 43.8% female), the incidence rate (IR) of IE was highest in the first 3 months after the intervention (TAVI, bioSAVR, mechSAVR: 23.61, 18.87, 16.65 per 1000 person-years, respectively). After matching, the rate of IE was higher in patients undergoing TAVI versus bioSAVR (n=2329 pairs, HR 1.56 [95% CI, 1.12-2.18]; incidence rate difference [IRD] 3.84 [95% CI,1.29-6.39] per 1000 person-years), and higher in bioSAVR versus mechSAVR (n=773, HR 2.27 [1.24-4.15]; IRD 4.57 [1.29-7.85] per 1000 person-years). The HRs for MACE were 2.10 [1.90-2.33] and 2.09 [1.58-2.77], respectively. CONCLUSIONS: For patients undergoing aortic valve replacement for native aortic valve stenosis, TAVI was associated with higher rates of IE than bioSAVR, as was bioSAVR when compared with mechSAVR.
3. Use of a Pulmonary Artery Catheter in Patients With Cardiogenic Shock - A Systematic Review and Meta-Analysis.
Across 12 nonrandomized studies, PAC-guided management of cardiogenic shock was associated with lower in-hospital mortality, with a clearer signal in heart failure–related shock than in ACS-related shock. Heterogeneity was substantial and certainty of evidence was very low, underscoring the need for randomized trials.
Impact: Clarifies when invasive hemodynamic monitoring may matter most in cardiogenic shock, informing triage and resource allocation while highlighting evidence gaps.
Clinical Implications: Consider early PAC placement in heart failure–related cardiogenic shock to guide therapy; use selectively in ACS-related shock. Implement protocols while awaiting RCTs, and integrate PAC data with multidisciplinary decision-making.
Key Findings
- Meta-analysis included 12 observational studies (out of 19 eligible), no RCTs.
- PAC use was associated with lower in-hospital mortality; effect stronger in heart failure–related CS than ACS-related CS.
- High heterogeneity and very low overall certainty due to inconsistencies and biases.
Methodological Strengths
- Systematic search across multiple databases with bias assessment.
- Subgroup and sensitivity analyses including time-to-event outcomes.
Limitations
- No randomized trials; all data observational with residual confounding.
- Substantial heterogeneity and varying definitions/protocols across studies.
Future Directions: Pragmatic RCTs comparing PAC-guided versus standard care in CS subtypes; standardized hemodynamic protocols and integration with mechanical circulatory support strategies.
BACKGROUND: A pulmonary artery catheter (PAC) provides detailed hemodynamic data, and managing a patient with cardiogenic shock (CS) using a PAC potentially improves patient outcomes. Therefore, in this systematic review and meta-analysis we aimed to evaluate whether a PAC is associated with better outcomes in patients with CS. METHODS AND RESULTS: Studies comparing PAC and non-PAC management in patients with CS were identified from the PubMed, Web of Science, and CENTRAL databases. There were no randomized controlled trials (RCTs). Of the 19 studies that met the inclusion criteria, 12 without a critical risk of bias were analyzed. PAC use was associated with lower in-hospital mortality when evaluated as a dichotomous outcome. Similar trends were observed in the time-to-event analyses. Substantial heterogeneity was observed across the studies. Subgroup analysis revealed better outcomes with PAC in patients with CS related to heart failure, but not in those with acute coronary syndrome. Sensitivity analyses, which included studies with a critical risk of bias, showed consistent trends favoring PAC use for crude in-hospital mortality. The overall certainty of the evidence was very low because of inconsistencies and biases. CONCLUSIONS: The PAC-guided CS management was associated with better in-hospital mortality, particularly in patients with heart failure-related CS. However, RCTs that evaluated the efficacy of PAC use as a primary purpose were not included, necessitating further RCTs to confirm these findings.